FDA Issues First Office of Surveillance and Epidemiology Annual Report, 2020 - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. FDA Issues First Office of Surveillance and Epidemiology Annual Report, 2020 Today, the Food and Drug Administration issued the first Office of Surveillance and Epidemiology (OSE) annual report. The  2020 Office of Surveillance and Epidemiology Annual Report highlights the OSE's  key initiatives to improve public health by reviewing and assessing the safety of medicines, with a special focus on its efforts to respond to the COVID-19 pandemic.  In 2020, OSE served a vital role in the Food and Drug Administration's response to COVID-19. During the pandemic, OSE staff monitored and assessed the safety and supply of novel and re-purposed medicines, including those under emergency use authorization, used to treat COVID-19; OSE also provided guidance on how to adapt risk evaluation and mitigation strategies (REMS) programs during a pandemic. Additionally, OSE has collaborated with international regulatory partners to develop common protocols to study the effects of drugs used to treat COVID-19.  The 2020 annual report provides insight into OSE's key initiatives to detect, assess, prevent, and monitor the risks of medicines. They look forward to continuing their mission in 2021.   View Full Report This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA